Wire · opportunities
Groundbreaking Pancreatic Cancer Drug Shows Promise in Lung Cancer
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 4 September 2026 · Fusion42 review
The oral RAS inhibitor daraxonrasib, recently FDA-approved for metastatic pancreatic cancer, showed promising response rates from 31% to 37% in a phase I/II trial for previously treated metastatic RAS-mutant non-small cell lung cancer patients. This drug offers a new targeted therapy option, with a notable response compared to traditional second-line treatments like docetaxel.
This Wire brief sits within Fusion42's coverage of Biotech, and 48 sources have reported it between 26 Aug 2026 and 16 Oct 2026.
◆ ◆ The Wire takeaway
You sell lung cancer treatments. Daraxonrasib's higher response rates than docetaxel mean you need to update your pipeline and go see oncologists demanding this new option before docetaxel becomes obsolete. This shift opens a fresh market for targeted RAS therapies replacing older chemotherapy.
◆ Coverage
48 sources · first reported 26 Aug 2026 · latest 16 Oct 2026
◆ Topics